Phosphoproteomics identification of ERK-dependent activation of Rps6kb1 in cardiac hypertrophy
Authors:
- Chao LiCLChao Li
- Pengfei ZhangPZPengfei Zhang
- Kai ZhangKZKai Zhang
- Jane A. CookJCJane A. Cook
- Weidan SongWSWeidan Song
- Megan VirostekMVMegan Virostek
- Lily A. SlotabecLSLily A. Slotabec
- Nadiyeh RouhiNRNadiyeh Rouhi
- Mohammed HazariMHMohammed Hazari
- Michael I. AdenawoolaMichael I. Adenawoola
- Xiaofei LiuXLXiaofei Liu
- Hao ZhangHZHao Zhang
Open Access
- 8 January 2026
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (4)
Abstract
Cardiomyocyte growth is tightly controlled by multiple signaling pathways. Identification of master kinases in this process is essential in exploring potential targets for the treatment of pathological cardiac hypertrophy and heart failure. Here we identified the mTOR-independent activation of ribosomal protein S6 kinase b1 (Rps6kb1) during cardiomyocyte growth. By utilizing phosphoproteomics in primary neonatal rat ventricular myocytes, we revealed Rps6kb1 as one of most activated kinases under growth stimulation. We further demonstrated the role of Rps6kb1 phosphorylation in pathological cardiac hypertrophy and heart failure. We showed that the phosphorylation of multiple sites in Rps6kb1, including T367 in the kinase domain and S418/T421/S424 in the C-terminal domain, is not directly regulated by the activity of mTOR but coupled with the activation of the MEK1/ERK axis. In mice, cardiomyocyte-specific deletion of Rps6kb1 significantly inhibited both constitutively active ERK– and pressure overload–induced cardiac hypertrophy. In contrast, cardiomyocyte-specific overexpression of wild-type Rps6kb1, rather than the phosphorylation-defective mutant, elevated cardiac hypertrophy and augmented pressure overload–induced heart failure. In conclusion, our findings reveal that the MEK/ERK axis primes Rps6kb1 activation through phosphorylation of 2 separate domains of Rps6kb1, which may play an essential role in cardiac hypertrophy and heart failure under hemodynamic stress.Keywords
Funding Information
- American Health Assistance Foundation (23TPA1077069,947398)
- American Diabetes Association Research Foundation (7-20-IBS-218,7-21-PDF-158,1-19-JDF-082)
- National Heart, Lung, and Blood Institute (HL-171309)
This publication has 39 references indexed in Scilit:
- Multisite Phosphorylation of S6K1 Directs a Kinase Phospho-code that Determines Substrate SelectionMolecular Cell, 2019
- S6K1 Is Required for Increasing Skeletal Muscle Force during HypertrophyCell Reports, 2016
- C. elegans S6K Mutants Require a Creatine-Kinase-like Effector for Lifespan ExtensionCell Reports, 2016
- Fibroblast-mediated pathways in cardiac hypertrophyJournal of Molecular and Cellular Cardiology, 2014
- Genetic Removal of p70 S6 Kinase 1 Corrects Molecular, Synaptic, and Behavioral Phenotypes in Fragile X Syndrome MiceNeuron, 2012
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensationTrends in Biochemical Sciences, 2011
- S6K1 Plays a Critical Role in Early Adipocyte DifferentiationDevelopmental Cell, 2010
- mTOR and S6K1 Mediate Assembly of the Translation Preinitiation Complex through Dynamic Protein Interchange and Ordered Phosphorylation EventsCell, 2005
- A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformationCurrent Biology, 1998
- An array of insulin-activated, proline-directed serine/threonine protein kinases phosphorylate the p70 S6 kinase.Journal of Biological Chemistry, 1992